Myotomy In Situ for Essential Blepharospasm Refractory to Botulinum Toxin

被引:5
作者
Lai, Hsin-Ti [1 ]
Chen, Austin D. [2 ]
Lee, Su-Shin [1 ,2 ]
Lin, Yi-Hui [3 ]
Lai, Chung-Sheng [1 ,2 ]
机构
[1] Kaohsiung Med Univ Hosp, Div Plast Surg, Dept Surg, 100 Tzyou 1st Rd, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ Hosp, Dept Neurol, Kaohsiung, Taiwan
关键词
blepharospasm; blepharoptosis; myectomy; myotomy in situ; apraxia of lid opening; UPPER EYELID MYECTOMY; SURGICAL-MANAGEMENT; PROTRACTOR MYECTOMY; APRAXIA; SURGERY;
D O I
10.1097/SAP.0000000000002182
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Full myectomy is recommended for benign essential blepharospasm (BEB) refractory to botulinum toxin (BT) treatment, but long-term swelling, scar contracture, hollow appearance, and unnatural contour of the eyelids are common postoperative complications. We present myotomy in situ to minimize these adverse outcomes. Methods The redundant eyelid skin with its underlying muscle is resected first, and myotomy in situ is performed by completely cutting the residual orbicularis oculi muscles into multiple cubes and down to the subcutaneous layer, and then cutting the procerus and corrugator muscles down to the periosteum. Patient demographics, medical treatment history, BT injection history, blepharoptosis correction techniques, associated surgical procedures, and aesthetic outcomes were analyzed. Preoperative and postoperative BT injection dosage and frequency, as well as modified disability scores, were compared using paired Studentttests. Results Twenty-five patients underwent this technique. Their average +/- SD age was 64.4 +/- 8.9 years, with average postoperative follow-up occurring 17.0 +/- 8.0 months. Associated diseases included blepharoptosis (88%) and apraxia of lid opening (44%). There were no postoperative hematoma, seroma, scar contracture, and depressed hollow eyelid contours. Preoperative to postoperative assessments revealed improvements in mean BT injection interval (10.4 +/- 2.1 to 14.6 +/- 2.9 weeks,P< 0.001), BT injection dosage (44.4 +/- 13.3 to 28.1 +/- 6.7 units,P< 0.001), and modified disability score (15.3 +/- 3.0 to 2.8 +/- 2.2,P< 0.001). All patients were highly satisfied with functional and aesthetic surgical outcomes (4.5 +/- 0.6 on Likert scale). Conclusions Myotomy in situ is effective for patients with BEB who are refractory to BT treatment, with therapeutic benefits similar to that of full myectomy with the ability to maintain favorable cosmetic results. Relative high incidence of blepharoptosis and apraxia of lid opening in patients with refractory BEB was reported. Simultaneous correction of the ptosis can further optimize outcomes.
引用
收藏
页码:S74 / S79
页数:6
相关论文
共 50 条
  • [1] Selective Myectomy and Myotomy In Situ for the Management of Refractory Blepharospasm in Meige Syndrome
    Lai, Chung-Sheng
    Wang, Yu-Chi
    Ramachandran, Savitha
    Chang, Yang-Pei
    Huang, Shu-Hung
    Hsieh, Meng-Chien Willie
    ANNALS OF PLASTIC SURGERY, 2023, 90 (01) : S84 - S88
  • [2] Therapy of Benign Essential Blepharospasm with Botulinum Toxin
    Kaltenmaier, Matthias
    Vanselow, Karoline
    Rollnik, Jens
    Maschke, Matthias
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2019, 87 (07) : 355 - 360
  • [3] Unilateral pallidotomy for blepharospasm refractory to botulinum toxin injections
    Horisawa, S.
    Kawamata, T.
    Taira, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (07) : E39 - E40
  • [4] Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm
    Wabbels, Bettina
    Jost, Wolfgang H.
    Roggenkaemper, Peter
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (06) : 925 - 943
  • [5] Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm
    Bettina Wabbels
    Wolfgang H. Jost
    Peter Roggenkämper
    Journal of Neural Transmission, 2011, 118 : 925 - 943
  • [6] BOTULINUM TOXIN AS A TREATMENT FOR BLEPHAROSPASM
    Duarte, Alexia
    Leonel dos Santos, Paola Nabhan
    Ghizoni Teive, Helio Afonso
    TOXICON, 2021, 190 : S18 - S18
  • [7] The good toxin: 10 years of experience with botulinum toxin A in the treatment of benign essential blepharospasm
    Lai, Kenneth K. H.
    Kuk, Andrew K. T.
    Chan, Edwin
    Ko, Simon T. C.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (03) : 1345 - 1350
  • [8] Botulinum toxin for benign essential blepharospasm: A systematic review and an algorithmic approach
    Rayess, Y. A.
    Awaida, C. J.
    Jabbour, S. F.
    Ballan, A. S.
    Sleilati, F. H.
    Abou Zeid, S. M.
    Nasr, M. W.
    REVUE NEUROLOGIQUE, 2021, 177 (1-2) : 107 - 114
  • [9] Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm
    Shukla, Aparna Wagle
    Hu, Wei
    Legacy, Joseph
    Deeb, Wissam
    Hallett, Mark
    BRAIN STIMULATION, 2018, 11 (03) : 645 - 647
  • [10] Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm
    Park, Dae Il
    Shin, Hyun Min
    Lee, Sang Yeul
    Lew, Helen
    ACTA OPHTHALMOLOGICA, 2013, 91 (02) : e108 - e112